Plasminogen Activator Inhibitor Recombinant 

Plasminogen Activator Inhibitor (PAI) recombinant proteins are engineered versions of naturally occurring PAIs, which are critical regulators of fibrinolysis and proteolytic pathways. These inhibitors control the activity of plasminogen activators such as tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), thereby modulating the conversion of plasminogen to plasmin, a key enzyme in clot breakdown. Recombinant PAI proteins, including PAI-1 and PAI-2, are widely used in thrombosis research, cancer studies, and drug discovery.

Content of PAI Recombinant Proteins

• Expression Systems:
  • Bacterial Systems: Used for high-yield production of recombinant PAI proteins, often lacking glycosylation.
  • Mammalian Systems: Essential for generating glycosylated, full-length PAIs with native post-translational modifications.
  • Insect Systems: Suitable for large-scale production of bioactive PAIs.
• Post-Translational Modifications:
  • Glycosylation enhances protein stability and activity.
  • Oxidation-sensitive residues may require protection during expression to retain activity.
• Validation:
  • Functional assays to confirm inhibitory activity against tPA and uPA.
  • Purity assessed using SDS-PAGE, Western blotting, and mass spectrometry.

Applications of PAI Recombinant Proteins

• Cancer Research:
  • Explore the role of PAI-1 and PAI-2 in tumor progression, metastasis, and angiogenesis.
  • Screen inhibitors targeting PAI-tPA/uPA interactions as potential cancer therapeutics.
• Structural Biology:
  • Recombinant PAIs facilitate the determination of high-resolution structures of PAI-enzyme complexes.
  • Provide insights into the conformational changes during the inhibitory process.
• Wound Healing and Tissue Remodeling Studies:
  • Investigate the role of PAIs in extracellular matrix remodeling, critical in wound repair and fibrotic diseases.
  • Study PAI-mediated regulation of proteolytic activity during cell migration and adhesion.
• Biomarker Development:
  • PAI-1 serves as a biomarker for cardiovascular disease risk and cancer prognosis.
  • Recombinant PAI proteins are used to validate diagnostic assays for clinical applications.

By providing biologically active and reproducible tools, recombinant PAI proteins are essential for advancing research in fibrinolysis, cancer biology, and therapeutic development targeting proteolytic and coagulation pathways.